Biogen CEO to step down; drugmaker pulls back on Alzheimer's dr

  • Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm



    Biogen said on Tuesday (May 3) that Chief Executive Michel Vounatsos will step down and that the company is pulling back on selling its Alzheimer's drug Aduhelm after the US government's Medicare program restricted coverage of the controversial treatment to patients in clinical trials.

    ฝาก 1 บาท รับ 50 กดรับเอง provide free slots funding as a web service for easy-to-break slot games, get fast money, increase free bet capital for slot players.

    Vounatsos, who was named as the CEO in 2016, will continue in his role until a successor is appointed, the company said. Under his leadership, the US biotech developed and launched several important growth drivers including spinal muscular atrophy drug Spinraza and multiple sclerosis drug Vumerity.

    Aduhelm was expected to be the company's next big blockbuster treatment, but controversy over its approval without clear evidence of patient benefit and the US decision to severely limit access appears to have doomed its prospects.

    Biogen said on Tuesday it was looking at "substantially" eliminating commercial infrastructure related to Aduhelm and plans for more cost cuts, in addition to the current program to save US$500 million annually.

    Biogen last month decided towithdraw its marketing application for Aduhelm in Europe after failing to convince the European regulator of the treatment's benefits.

    The company said it will retain minimal resources to make Aduhelm available to patients currently taking the drug in the United States.

    Mizuho Securities analyst Salim Syed said the move will slow the company's cash burn and that the CEO transition will be received positively by the market, as many investors had been calling for it.